In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who ...

Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...

ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...

Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves—insights that could help researchers develop more effective treatment strategies.

Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...

July 31, 2025, NEW YORK – The immune system is a major determinant of how patients respond to standard treatments for ovarian cancer, the leading cause of death from gynecological malignancies. But ...

Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...

More than two-thirds of deaths from ovarian cancer are attributable to high-grade serous carcinoma. In one particularly ...

Ovarian cancer reprograms the omentum to shield hidden tumors. New research suggests total omentectomy may curb recurrence and improve long-term outcomes.

A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...